Navigation Links
Faruqi & Faruqi, LLP is Investigating Peregrine Pharmaceuticals Inc. on Behalf of its Shareholders - PPHM
Date:4/9/2013

NEW YORK, April 9, 2013 /PRNewswire/ -- Faruqi & Faruqi, LLP, a national law firm concentrating on investor rights, consumer rights and the enforcement of federal antitrust laws, is investigating potential wrongdoing at Peregrine Inc. ("Peregrine" or the "Company") (NASDAQ: PPHM).  The investigation focuses on whether certain executive officers and directors of Peregrine breached their fiduciary duties by failing to disclose that: (1) there were major discrepancies between various patient sample test results and patient treatment code assignments; (2) the clinical data from the Company's randomized, double-blind placebo-controlled Phase II trial of bavituximab in second-line non-small cell lung cancer was misleading; and (3) as a result of the foregoing, the Company's positive statements about Peregrine's business, operations, and prospects, including those statements relating to the clinical data from the Company's randomized, double-blind placebo-controlled Phase II trial of bavituximab in second-line non-small cell lung cancer lacked sufficient support.

(Logo: http://photos.prnewswire.com/prnh/20120119/MM38856LOGO)

On September 24, 2012 Peregrine disclosed that during the course of preparing for an end-of-phase II meeting with regulatory authorities and following recent data announcements from its randomized, double-blind placebo-controlled Phase II trial of bavituximab in second-line non-small cell lung cancer, the Company discovered major conflicts between patient sample test results and patient treatment code assignments. Moreover, Peregrine informed investors that they should no longer depend on clinical data that the Company had previously reported from its Phase II bavituximab trial in patients with second-line non-small cell lung cancer.  Shareholders interested in seeking to recover damages on behalf of Peregrine and to implement corporate governance measures designed to prevent future misconduct should contact the firm.

Request more information now by clicking here: www.faruqilaw.com/Peregrine.

Faruqi & Faruqi, LLP is a national law firm which represents investors and individuals in class action and derivative litigation.  The firm is focused on providing exemplary legal services in the areas of securities, shareholder, antitrust and consumer litigation, through all phases of litigation.  The firm has an experienced trial team which has achieved significant victories on behalf of the firm's clients.

If you hold PPHM shares and you would like to discuss your legal rights, visit www.faruqilaw.com/Peregrine.  You can also contact us by calling Michael J. Hynes free at 877-247-4292 or at 215-277-5770 or by sending an e-mail to mhynes@faruqilaw.com.

Contact:

Faruqi & Faruqi, LLP
Michael J. Hynes, Esq.
101 Greenwood Avenue Suite 600
Jenkintown, PA 19046
Telephone: (877) 247-4292 or (215) 277-5770
E-mail: mhynes@faruqilaw.com

(NASDAQ: PPHM)

Attorney Advertising. (C) 2013 Faruqi & Faruqi, LLP.  The law firm responsible for this advertisement is Faruqi & Faruqi, LLP (www.faruqilaw.com).  Prior results do not guarantee or predict a similar outcome with respect to any future matter.  We welcome the opportunity to discuss your particular case.  All communications will be treated in a confidential manner.


'/>"/>
SOURCE Faruqi & Faruqi, LLP
Copyright©2012 PR Newswire.
All rights reserved

Related medicine technology :

1. Faruqi & Faruqi, LLP Encourages Investors Who Suffered Substantial Losses Investing in Chelsea Therapeutics International, Ltd. to Contact the Firm
2. Faruqi & Faruqi, LLP Announces Investigation of ViroPharma Incorporated
3. Faruqi & Faruqi, LLP Notifies Investors of June 4, 2012 Lead Plaintiff Deadline for the Class Action Filed Against Chelsea Therapeutics International
4. Faruqi & Faruqi, LLP is Investigating Pain Therapeutics Inc. on Behalf of its Shareholders (PTIE)
5. Faruqi & Faruqi, LLP Encourages Investors Who Suffered Substantial Losses Investing In American Oriental Bioengineering Inc. To Contact The Firm Regarding The August 22, 2012 Lead Plaintiff Deadline
6. Faruqi & Faruqi, LLP is Investigating AmerisourceBergen Corporation on Behalf of its Shareholders
7. Smith & Nephew launches revolutionary open-architecture suture anchor for rotator cuff repair with greater pullout strength than competitors[i]
8. Thomson Reuters Launches New Mobile Oncology Decision Support Solution for R&D Pharmaceutical Leaders
9. Biopharma M&A Trends Hold Steady, But Deals Declined in 2011
10. Foundation for Managed Care Pharmacy (FMCP) Presents Awards for 2012 National P&T Competition and Best Posters
11. Almost 50 Percent of the Glaucoma Patient Population Remains Untreated, Signifying a Vast Market for Glaucoma Pharmaceuticals, Finds Frost & Sullivan
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:9/6/2017)... , Sept. 6, 2017 Eli Lilly ... it will present new data for galcanezumab and lasmiditan, ... of the International Headache Society (IHC) taking place Sept. ... Lilly will highlight new, long-term data from an ... doses of galcanezumab (120 mg and 240 mg) for ...
(Date:9/5/2017)... Inc. has announced another milestone in their continued growth and success of the ... demands of customer engagements regionally.  ... office is located at 318 West Adams Street, Suite 1528, Chicago, IL ... Xyntek's recently opened Midwest office ... In addition ...
(Date:9/5/2017)... , Sept. 5, 2017  Just 18 months ... Insight is pleased to announce the appointment of three ... Tammy Wynne , Dominic Jones-Phillips and ... industry. Tammy ... team of market access writers. She has over ten ...
Breaking Medicine Technology:
(Date:9/19/2017)... , ... September 19, 2017 ... ... DACVIM, a board-certified veterinary oncologist, has agreed to serve as strategic adviser ... Dr. Tripp is founder of the Bridge Animal Referral Center (BARC) ...
(Date:9/19/2017)... Glen Cove, New York (PRWEB) , ... September 19, 2017 , ... ... that its dentist, Dr. Andrew Sami, was recently named one of the best dentists ... the leading lifestyle magazine for dental professionals nationwide. Every fall, the magazine features the ...
(Date:9/19/2017)... ... 2017 , ... When it comes to household safety, there are few priorities ... to keep babies and toddlers safe, and there's no better time for companies to ... to Check Labels, Brands that sell all kinds of common consumer products should spend ...
(Date:9/19/2017)... ... September 19, 2017 , ... Emergency ... the Certified Emergency Nurse (CEN®) certification according to a large-scale study ... of certification study, conducted by the Human Resources Research Organization (HumRRO) in late ...
(Date:9/18/2017)... (PRWEB) , ... September 19, 2017 , ... Sarantos ... Fiction Fantasy Book This December , Sarantos is proud to be the 1st (and ... off every new song release. A new song, music video, book chapter and behind ...
Breaking Medicine News(10 mins):